Thurston Springer Miller Herd & Titak Inc. Sells 2,027 Shares of Amgen Inc. $AMGN

Posted by George Bondi on Oct 14th, 2026

Thurston Springer Miller Herd & Titak Inc. lessened its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 67.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 985 shares of the medical research company’s stock after selling 2,027 shares during the quarter. Thurston Springer Miller Herd & Titak Inc.’s holdings in Amgen were worth $415,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. BlackRock Inc. lifted its stake in Amgen by 4.8% in the second quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock worth $17,874,974,000 after purchasing an additional 2,261,544 shares during the last quarter. State Street Corp grew its stake in shares of Amgen by 38.2% during the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock valued at $15,283,363,000 after buying an additional 11,656,755 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Amgen by 12.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,390,910 shares of the medical research company’s stock valued at $1,952,156,000 after buying an additional 605,928 shares during the last quarter. Bank of America Corp DE bought a new position in shares of Amgen during the second quarter valued at approximately $1,831,903,000. Finally, Invesco Ltd. raised its holdings in shares of Amgen by 7.2% in the fourth quarter. Invesco Ltd. now owns 4,788,460 shares of the medical research company’s stock worth $1,567,311,000 after buying an additional 321,173 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. UBS Group raised their price target on Amgen from $430.00 to $470.00 and gave the stock a “buy” rating in a research note on Friday, October 9th. Wall Street Zen downgraded Amgen from a “buy” rating to a “hold” rating in a research report on Saturday. Robert W. Baird upped their price objective on Amgen from $215.00 to $230.00 and gave the company an “underperform” rating in a research report on Wednesday, August 5th. Cantor Fitzgerald increased their target price on Amgen from $400.00 to $440.00 and gave the stock a “neutral” rating in a research note on Monday, October 5th. Finally, Jefferies Financial Group reiterated a “hold” rating and set a $410.00 target price on shares of Amgen in a research report on Wednesday, September 23rd. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $387.93.

Read Our Latest Analysis on AMGN

Amgen Trading Up 3.1%

Shares of NASDAQ AMGN traded up $12.85 during trading hours on Wednesday, reaching $425.69. The stock had a trading volume of 1,098,227 shares, compared to its average volume of 2,739,581. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. The firm has a market cap of $230.14 billion, a price-to-earnings ratio of 26.44, a P/E/G ratio of 3.01 and a beta of 0.41. The business’s fifty day moving average price is $414.16 and its two-hundred day moving average price is $373.24. Amgen Inc. has a 52-week low of $288.00 and a 52-week high of $447.03.

Amgen (NASDAQ:AMGN – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.62 by $0.67. The company had revenue of $10.05 billion for the quarter, compared to analysts’ expectations of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%. Amgen’s revenue was up 9.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Analysts expect that Amgen Inc. will post 22.94 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 21st were paid a dividend of $2.52 per share. The ex-dividend date was Friday, August 21st. This represents a $10.08 annualized dividend and a dividend yield of 2.4%. Amgen’s dividend payout ratio (DPR) is currently 62.65%.

Insider Buying and Selling at Amgen

In related news, SVP Rachna Khosla sold 2,000 shares of Amgen stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the completion of the sale, the senior vice president directly owned 6,404 shares in the company, valued at $2,642,098.28. The trade was a 23.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Nancy Grygiel sold 2,970 shares of the company’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the sale, the senior vice president directly owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 6,222 shares of company stock worth $2,540,926. Insiders own 0.85% of the company’s stock.

About Amgen

(Free Report)

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.